Rodec Pharma IPO Gets SEBI Approval

The Securities and Exchange Board of India (SEBI) has granted approval for the Initial Public Offer (IPO) of Rodec Pharma Ltd. on December 31, 2025. The approval allows the company to move ahead with the required steps to launch the IPO, subject to market conditions and additional regulatory clearances.

SEBI has confirmed that the approval will remain valid for 12 months from the date of issuance. The company is expected to announce further details, including timelines and pricing, as the process advances.

IPO Structure and Listing Details

The IPO will be a Book Build Issue consisting entirely of an offer for sale of up to 0.57 crore equity shares. Rodec Pharma Ltd. has proposed to list its shares on both NSE and BSE upon completion of the offering.

Khambatta Securities Ltd. will serve as the book running lead manager for the issue, ensuring coordination of the bidding and allocation processes. Bigshare Services Pvt. Ltd. has been appointed as the registrar, responsible for handling investor applications and share allotment procedures.

Offer Timeline and Pending Disclosures

Key IPO details such as issue dates, price bands, and lot size have not yet been announced. These details will be disclosed closer to the launch, as they remain dependent on prevailing market conditions and regulatory timelines.

The company will finalise these parameters in consultation with its advisors and market intermediaries. Investors are expected to monitor upcoming announcements for clarity on subscription schedules.

Company Overview and Operations

Incorporated in 1997, Rodec Pharma Ltd. operates in the animal healthcare segment, focusing on the manufacturing of animal feed supplements and the marketing of veterinary pharmaceutical drugs. The company follows an integrated business model that includes manufacturing, distribution, and marketing activities across various regions.

This structure enables the firm to maintain consistent supply capabilities and reach diverse customer bases. Its operations are designed to support scalability and efficiency in delivering veterinary health products.

Product Portfolio and Segment Coverage

Rodec Pharma Ltd.’s product portfolio includes veterinary pharmaceuticals and animal feed supplements catering to multiple therapeutic needs. The company offers 35 products and 29 variants across antibiotic, antispasmodic, ectoparasiticide, and nutritional supplement categories.

These products are used widely within the animal healthcare industry to support preventive and therapeutic care. The breadth of its portfolio strengthens its market positioning across different customer segments.

Read More: SEBI Plans Reforms to Ease Trading and Improve Market Efficiency.

Conclusion

Rodec Pharma Ltd. has received SEBI’s approval to move forward with its IPO, marking a significant step in its capital‑raising plan. The offer, comprising an offer for sale of 0.57 crore shares, will be listed on NSE and BSE upon completion.

With a strong product portfolio and an extensive distribution network, the company continues to strengthen its presence in the animal healthcare industry. Further IPO details are awaited as the company prepares for the next phase of the listing process.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.